MOTS-c vs SS-31
A comparison of MOTS-c and SS-31 as mitochondrial peptides, including mechanism differences, metabolic vs. membrane-protection focus, and current evidence context.
A comparison of MOTS-c and SS-31 as mitochondrial peptides, including mechanism differences, metabolic vs. membrane-protection focus, and current evidence context.
Overview
MOTS-c and SS-31 are both mitochondria-related peptides but represent fundamentally different classes and mechanisms. MOTS-c is a mitochondrial-derived peptide that acts as a metabolic regulator circulating systemically, while SS-31 is a synthetic tetrapeptide designed to target the inner mitochondrial membrane directly. They are sometimes discussed together in longevity and mitochondrial research, but the research questions they address are different.
Mechanism Comparison
MOTS-c is encoded in mitochondrial DNA and studied for its role as a peptide hormone modulating insulin sensitivity, metabolic adaptation, and exercise-related cellular responses. SS-31 acts by binding cardiolipin on the inner mitochondrial membrane, stabilizing the structure and reducing oxidative stress associated with mitochondrial dysfunction. MOTS-c research is largely metabolic in focus; SS-31 research is more centered on cytoprotection and mitochondrial structural integrity.
Dosing and Protocol Comparison
MOTS-c is typically studied via subcutaneous injection in animal models, with exercise-mimetic and metabolic research contexts. SS-31 has been studied both systemically and in cardiac or renal ischemia-reperfusion models. SS-31 also has clinical trial history as Elamipretide for Barth syndrome and heart failure, making it one of the few mitochondrial peptides with a formal clinical development pathway.
Evidence Comparison
SS-31 has the more developed clinical evidence base, anchored by human trials in heart failure and rare mitochondrial disease. MOTS-c research is primarily preclinical and mechanistic, with strong interest in aging and metabolic medicine but limited human data. Both are promising in the mitochondrial peptide field, but SS-31 is further along the translational path.